Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 8/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2322652 | 0.88 | BRD4 (0.31) | BRD4 | |
| SCHEMBL2322074 | 0.77 | BRD4 (0.38) | BRD4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL14638158 | 0.76 | BRD4 (0.30) | BRD4 | |
| SCHEMBL14637330 | 0.74 | BRD4 (0.30) | BRD4 | |
| SCHEMBL2321033 | 0.72 | MAPK11 (0.34) | — | |
| Methyl Alcohol SCHEMBL14121774 | 0.70 | MAPK11 (0.35) | — | |
| SCHEMBL2326510 | 0.65 | — | — | |
| SCHEMBL15878101 | 0.65 | — | — | |
| SCHEMBL15877857 | 0.65 | BTK (0.31) | — | |
| SCHEMBL2322567 | 0.65 | SMN1; SMN2 (0.47) | PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2534151-B1 | 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS | MERCK SHARP & DOHME (NL) | 2018-11-14 | — | — | EP | disclosed |
| US-8658794-B2 | 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds as Lck inhibitors and uses thereof | MERCK SHARP & DOHME B.V. (NL) | 2014-02-25 | — | — | US | disclosed |
| EP-2534151-A1 | 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS | MSD Oss B.V. (NL) | 2012-12-19 | — | — | EP | disclosed |
| US-20120309966-A1 | 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS | N.V. ORGANON (NL) | 2012-12-06 | — | — | US | disclosed |
| WO-2011095556-A1 | 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS | N.V. ORGANON (NL) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309966-A1 | 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS | LCK, ZAP70, FYN | BRD4 1046/4885PDE4A 629/4885PDE4B 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.